OrbiMed-backed Prelude raises $60M to take PRMT5 program through clinical POC

With $60 million in new series B funding, Prelude hopes to obtain clinical proof-of-concept data for its lead PRMT5 inhibitor for solid tumors or blood cancers.

OrbiMed Advisors and one other undisclosed institutional investor

Read the full 338 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE